245 related articles for article (PubMed ID: 36282000)
1. The diverse arsenal of type III CRISPR-Cas-associated CARF and SAVED effectors.
Steens JA; Salazar CRP; Staals RHJ
Biochem Soc Trans; 2022 Oct; 50(5):1353-1364. PubMed ID: 36282000
[TBL] [Abstract][Full Text] [Related]
2. Type III CRISPR-Cas: beyond the Cas10 effector complex.
Stella G; Marraffini L
Trends Biochem Sci; 2024 Jan; 49(1):28-37. PubMed ID: 37949766
[TBL] [Abstract][Full Text] [Related]
3. Csx3 is a cyclic oligonucleotide phosphodiesterase associated with type III CRISPR-Cas that degrades the second messenger cA
Brown S; Gauvin CC; Charbonneau AA; Burman N; Lawrence CM
J Biol Chem; 2020 Oct; 295(44):14963-14972. PubMed ID: 32826317
[TBL] [Abstract][Full Text] [Related]
4. Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage.
Athukoralage JS; McQuarrie S; Grüschow S; Graham S; Gloster TM; White MF
Elife; 2020 Jun; 9():. PubMed ID: 32597755
[TBL] [Abstract][Full Text] [Related]
5. The CRISPR effector Cam1 mediates membrane depolarization for phage defence.
Baca CF; Yu Y; Rostøl JT; Majumder P; Patel DJ; Marraffini LA
Nature; 2024 Jan; 625(7996):797-804. PubMed ID: 38200316
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the cyclic oligoadenylate signaling pathway of type III CRISPR systems.
Rouillon C; Athukoralage JS; Graham S; Grüschow S; White MF
Methods Enzymol; 2019; 616():191-218. PubMed ID: 30691643
[TBL] [Abstract][Full Text] [Related]
7. Interference Requirements of Type III CRISPR-Cas Systems from Thermus thermophilus.
Karneyeva K; Kolesnik M; Livenskyi A; Zgoda V; Zubarev V; Trofimova A; Artamonova D; Ispolatov Y; Severinov K
J Mol Biol; 2024 Mar; 436(6):168448. PubMed ID: 38266982
[TBL] [Abstract][Full Text] [Related]
8. Enzymatic properties of CARF-domain proteins in
Ding J; Schuergers N; Baehre H; Wilde A
Front Microbiol; 2022; 13():1046388. PubMed ID: 36419420
[TBL] [Abstract][Full Text] [Related]
9. Evolutionary and functional classification of the CARF domain superfamily, key sensors in prokaryotic antivirus defense.
Makarova KS; Timinskas A; Wolf YI; Gussow AB; Siksnys V; Venclovas Č; Koonin EV
Nucleic Acids Res; 2020 Sep; 48(16):8828-8847. PubMed ID: 32735657
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of cyclic oligoadenylate degradation by ancillary Type III CRISPR-Cas ring nucleases.
Molina R; Jensen ALG; Marchena-Hurtado J; López-Méndez B; Stella S; Montoya G
Nucleic Acids Res; 2021 Dec; 49(21):12577-12590. PubMed ID: 34850143
[TBL] [Abstract][Full Text] [Related]
11. Regulation of cyclic oligoadenylate synthesis by the
Nasef M; Muffly MC; Beckman AB; Rowe SJ; Walker FC; Hatoum-Aslan A; Dunkle JA
RNA; 2019 Aug; 25(8):948-962. PubMed ID: 31076459
[TBL] [Abstract][Full Text] [Related]
12. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
[TBL] [Abstract][Full Text] [Related]
13. Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers.
Niewoehner O; Garcia-Doval C; Rostøl JT; Berk C; Schwede F; Bigler L; Hall J; Marraffini LA; Jinek M
Nature; 2017 Aug; 548(7669):543-548. PubMed ID: 28722012
[TBL] [Abstract][Full Text] [Related]
14. The CRISPR ancillary effector Can2 is a dual-specificity nuclease potentiating type III CRISPR defence.
Zhu W; McQuarrie S; Grüschow S; McMahon SA; Graham S; Gloster TM; White MF
Nucleic Acids Res; 2021 Mar; 49(5):2777-2789. PubMed ID: 33590098
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive search for accessory proteins encoded with archaeal and bacterial type III CRISPR-cas gene cassettes reveals 39 new cas gene families.
Shah SA; Alkhnbashi OS; Behler J; Han W; She Q; Hess WR; Garrett RA; Backofen R
RNA Biol; 2019 Apr; 16(4):530-542. PubMed ID: 29911924
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the RNA and DNA nuclease activities required for Pyrococcus furiosus Type III-B CRISPR-Cas immunity.
Foster K; Grüschow S; Bailey S; White MF; Terns MP
Nucleic Acids Res; 2020 May; 48(8):4418-4434. PubMed ID: 32198888
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas III-A Csm6 CARF Domain Is a Ring Nuclease Triggering Stepwise cA
Jia N; Jones R; Yang G; Ouerfelli O; Patel DJ
Mol Cell; 2019 Sep; 75(5):944-956.e6. PubMed ID: 31326273
[TBL] [Abstract][Full Text] [Related]
18. The structure of a Type III-A CRISPR-Cas effector complex reveals conserved and idiosyncratic contacts to target RNA and crRNA among Type III-A systems.
Paraan M; Nasef M; Chou-Zheng L; Khweis SA; Schoeffler AJ; Hatoum-Aslan A; Stagg SM; Dunkle JA
PLoS One; 2023; 18(6):e0287461. PubMed ID: 37352230
[TBL] [Abstract][Full Text] [Related]
19. Antiviral type III CRISPR signalling via conjugation of ATP and SAM.
Chi H; Hoikkala V; Grüschow S; Graham S; Shirran S; White MF
Nature; 2023 Oct; 622(7984):826-833. PubMed ID: 37853119
[TBL] [Abstract][Full Text] [Related]
20. Genetic Dissection of the Type III-A CRISPR-Cas System Csm Complex Reveals Roles of Individual Subunits.
Mogila I; Kazlauskiene M; Valinskyte S; Tamulaitiene G; Tamulaitis G; Siksnys V
Cell Rep; 2019 Mar; 26(10):2753-2765.e4. PubMed ID: 30840895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
